Multiple sclerosis

Multiple sclerosis
Name	Multiple sclerosis
Field	Neurology
Duration	Chronic
Types	Relapsing–remitting, Secondary progressive, Primary progressive
Causes	Autoimmune, genetic, environmental
Risks	Genetics, latitude, smoking, Epstein–Barr virus
Diagnosis	Clinical, MRI, CSF analysis, evoked potentials
Treatment	Disease-modifying therapies, corticosteroids, symptomatic therapy
Prognosis	Variable

Multiple sclerosis

Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system affecting the brain, spinal cord, and optic nerves. It presents with variable neurological deficits and a relapsing or progressive course, requiring multidisciplinary care from specialists and institutions experienced in neurology and rehabilitation.

Introduction

Multiple sclerosis is characterized by immune-mediated damage to myelin and axons within the central nervous system, producing lesions detectable by magnetic resonance imaging and pathological analysis in neuropathology centers associated with universities and hospitals. Historical descriptions influenced neurologists, neuropathologists, and clinicians at institutions such as Guy's Hospital, Charité – Universitätsmedizin Berlin, Mayo Clinic, and research groups at NIH and Karolinska Institutet. Major advances in disease modification emerged from collaborations among pharmaceutical companies, academic centers, and regulatory agencies like the Food and Drug Administration and European Medicines Agency.

Signs and symptoms

Patients may present with visual impairment linked to lesions of the optic nerve reported by ophthalmology departments including Moorfields Eye Hospital surgeons, motor weakness described in case series from Massachusetts General Hospital neurologists, sensory disturbances noted in outpatient clinics at Johns Hopkins Hospital, and gait impairment documented by rehabilitation units at Spaulding Rehabilitation Hospital. Common episodic findings—optic neuritis, transverse myelitis, internuclear ophthalmoplegia—are also discussed in textbooks by authors at Oxford University Press, Cambridge University Press, and professional societies such as the American Academy of Neurology and the European Academy of Neurology.

Causes and pathophysiology

Pathogenesis implicates autoreactive lymphocytes and environmental triggers explored in cohort studies at Karolinska Institutet, Harvard Medical School, and University of Oxford. Genetic associations involving HLA alleles were reported in genomic studies conducted by consortia including researchers from Wellcome Trust initiatives and the International Multiple Sclerosis Genetics Consortium. Infectious hypotheses cite seroepidemiology linking Epstein–Barr virus infection to increased risk in longitudinal studies from CDC collaborators and academic centers. Smoking as a risk modifier was confirmed in epidemiological reports from University of California, San Francisco and University of Toronto. Pathophysiological mechanisms involving demyelination, remyelination failure, microglial activation, and axonal transection are subjects of research at laboratories in Stanford University, Massachusetts Institute of Technology, and University College London.

Diagnosis

Diagnosis relies on demonstrating dissemination in space and time using clinical evaluation, magnetic resonance imaging protocols standardized by neuroradiology groups at Radiological Society of North America, cerebrospinal fluid analysis for oligoclonal bands evaluated in neuroimmunology labs at Mayo Clinic, and neurophysiological testing such as evoked potentials employed in clinical centers including Cleveland Clinic. Differential diagnosis considerations reference mimics seen in neuropathology and rheumatology services at Johns Hopkins School of Medicine and specialist centers in Mayo Clinic Arizona and UCSF Medical Center.

Classification and disease course

Contemporary classification distinguishes relapsing–remitting, secondary progressive, and primary progressive courses as outlined in consensus statements from the International Advisory Committee on Clinical Trials of MS and practice guidelines by the American Academy of Neurology and the European Committee for Treatment and Research in Multiple Sclerosis. Clinical outcome measures and disability scales, frequently used in clinical trials at academic centers like Imperial College London and University of British Columbia, include the Expanded Disability Status Scale developed by registries and investigators collaborating with international MS networks.

Management and treatment

Disease-modifying therapies originated from randomized controlled trials organized by cooperative groups linked to institutions such as Oxford University Hospitals, Vanderbilt University Medical Center, and pharmaceutical research departments collaborating with regulators like the Food and Drug Administration. Immunomodulatory and immunosuppressive agents—interferon preparations, monoclonal antibodies, oral small molecules—are deployed according to protocols from the European Medicines Agency and national guidelines from agencies including NICE and the American Academy of Neurology. Acute relapses are managed with high-dose corticosteroids in inpatient and outpatient services at general hospitals like Addenbrooke's Hospital and infusion centers at tertiary facilities. Symptomatic therapies for spasticity, pain, bladder dysfunction, and fatigue are coordinated with multidisciplinary teams from rehabilitation centers and specialty clinics such as National Rehabilitation Hospital and university-affiliated physiotherapy departments.

Epidemiology and prognosis

Epidemiological patterns show variable prevalence influenced by latitude and ancestry in population studies performed by public health institutions including Public Health England, Statens Serum Institut, and the World Health Organization. Incidence and prevalence estimates derive from national registries maintained by academic centers in Sweden, Denmark, Canada, and the United States. Prognosis is heterogeneous; long-term outcomes reported in cohort studies from University of Oxford, University of Basel, and Karolinska Institutet identify factors associated with disability accumulation, while rehabilitation and symptomatic management by specialized centers can improve quality of life and functional outcomes.

Category:Neurological disorders